BRAINOMIX Competitors

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).

In everything we do, we strive to innovate and perfect ways to help save people’s lives. Utilizing state-of-the-art deep learning technology that is “always-on”, we provide artificial intelligence solutions that support and enhance the impact of radiologist diagnostic power, in real-time. By combining our expertise in Artificial Intelligence, Machine Learning, and Software, we help expedite patient treatment and improve the quality of care.

MeVis Medical Solutions was founded in 1997 and is one of the world's leading independent developers and providers of software products for image-based medicine, particularly digital radiology. The importance and complexity of medical data acquired from today's imaging modalities like computer tomography, magnetic resonance tomography, ultrasound and mammography is growing steadily. MeVis products analyze and process this data to provide medical professionals crucial information for early diagnosis and therapy in the areas of cancer, particularly breast cancer, neurological disorders and lung conditions. The company develops its software solutions in close cooperation with world's leading clinical experts and has established longstanding industry partnerships with original equipment manufacturers (OEMs) of imaging devices and sells its products primarily through these channels. MeVis Medical Solutions AG recorded a revenue of 17.0 million € in fiscal year 2023/2024 and an average of 116 highly qualified employees. Data privacy regarding social media of MeVis Medical Solutions AG: https://www.mevis.de/en/data-privacy/data-privacy-social-media Site notice of MeVis Medical Solutions AG: https://www.mevis.de/en/imprint